Cumberland Pharmaceuticals (CPIX) Equity Average (2011 - 2026)

Cumberland Pharmaceuticals has disclosed Equity Average across 16 years of filings, most recently posting $23.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $23.1 million, down 9.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.1 million (down 9.24% YoY), and the FY2025 annual result was $23.7 million, down 8.45% from the prior year.
• Equity Average came in at $23.1 million for Q1 2026 at Cumberland Pharmaceuticals, down from $25.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $41.7 million in Q1 2022 to a low of $23.1 million in Q1 2026.
• The 5-year median for Equity Average is $28.2 million (2024), against an average of $31.3 million.
• Across the five-year window, Equity Average plunged 30.34% in 2024 and increased 7.8% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Equity Average stood at $37.4 million in 2022, then declined by 13.29% to $32.5 million in 2023, then dropped by 27.57% to $23.5 million in 2024, then gained by 7.8% to $25.3 million in 2025, then decreased by 8.87% to $23.1 million in 2026.
• The last three Equity Average figures came in at $23.1 million (Q1 2026), $25.3 million (Q4 2025), and $26.7 million (Q3 2025), per Business Quant data.